Neurogene Inc. 8-K — AI Bull & Bear Analysis

The filing confirms that Neurogene has finished dosing patients in its pivotal trial, a move that typically precedes a major valuation event based on clinical results. However, the lack of accompanying financial data in the report highlights the tension between clinical progress and capital requirements. Investors are left to weigh the potential of a breakthrough therapy against the immediate risk of a liquidity crunch as the company enters the most expensive phase of drug development.